Showing results (301-310 of 457) with videos related to
Sort By:
Pageof 46
Cold Spring Harbor Molecular Case Studies|August 31, 2023
The importance of escalating molecular diagnostics in patients with low-grade pediatric brain cancerMajd Al Assaad, Gunes Gundem, Benjamin Liechty, et al.European Urology Oncology|June 16, 2019
Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 TrialsMarco Bandini, Alberto Briganti, Elizabeth R Plimack, et al.The Lancet. Oncology|April 19, 2015
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trialYohann Loriot, Kurt Miller, Cora N Sternberg, et al.Clinical Genitourinary Cancer|March 28, 2017
Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL TrialJoshi J Alumkal, Simon Chowdhury, Yohann Loriot, et al.European Urology|August 25, 2012
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settingsCora N Sternberg, Joaquim Bellmunt, Guru Sonpavde, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2010
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trialCora N Sternberg, Ian D Davis, Jozef Mardiak, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2023
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III TrialCora N Sternberg, Ian D Davis, Jozef Mardiak, et al.European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinomaMatthew I Milowsky, Christian Dittrich, Ignacio Durán, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 3, 2023
Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591Scott T Tagawa, Charlene Thomas, A Oliver Sartor, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 2021
Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trialA Jayaram, A Wingate, D Wetterskog, et al.Pageof 46